At the time of writing, Regulus Therapeutics Inc [RGLS] stock is trading at $1.23, up 23.00%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The RGLS shares have gain 3.36% over the last week, with a monthly amount drifted -22.15%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on August 02, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. Previously, Leerink Partners started tracking the stock with Outperform rating on March 18, 2024, and set its price target to $6. On March 28, 2018, B. Riley FBR Inc. initiated with a Neutral rating and assigned a price target of $1 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $2 on January 05, 2018. Chardan Capital Markets reiterated its recommendation of a Buy and reduced its price target to $2.50 on June 13, 2017. Wedbush reiterated a Outperform rating for this stock on March 06, 2017, and downed its price target to $6. In a note dated January 30, 2017, Wells Fargo downgraded an Market Perform rating on this stock.
For the past year, the stock price of Regulus Therapeutics Inc fluctuated between $0.83 and $3.79. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $1.23 at the most recent close of the market.
Analyzing the RGLS fundamentals
Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -147.67%, Pretax Profit Margin comes in at -137.84%, and Net Profit Margin reading is -137.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.53 and Total Capital is -0.51. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.0633 points at the first support level, and at 0.8967 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.3433, and for the 2nd resistance point, it is at 1.4567.
Ratios To Look Out For
It is important to note that Regulus Therapeutics Inc [NASDAQ:RGLS] has a current ratio of 13.65. Also, the Quick Ratio is 13.65, while the Cash Ratio stands at 4.07.
Transactions by insiders
Recent insider trading involved Hagan Joseph P, Chief Executive Officer, that happened on Jan 30 ’25 when 50000.0 shares were purchased. Director, BALTIMORE DAVID completed a deal on Jan 30 ’25 to buy 19610.0 shares. Meanwhile, Sr. VP & General Counsel Aker Christopher Ray sold 38547.0 shares on Jan 13 ’25.
